Anika Therapeutics, Inc. 8-K

What Happened
Anika Therapeutics, Inc. (ANIK) filed an 8-K on February 26, 2026 to (1) announce its fourth-quarter and full-year results for the period ended December 31, 2025 (press release furnished as Exhibit 99.1) and (2) disclose a Transitional Services and General Release of Claims Agreement with Executive Vice President, General Counsel and Corporate Secretary David Colleran. Under the transition agreement dated February 26, 2026, Mr. Colleran will remain employed and provide services through the Anticipated Separation Date of May 1, 2026 unless he resigns or is terminated for Cause.

Key Details

• Press release dated February 26, 2026 announcing Q4 and full-year 2025 financial results (Exhibit 99.1 is furnished with the filing).
• Transitional Services and General Release of Claims Agreement executed Feb 26, 2026; Anticipated Separation Date is May 1, 2026.
• Mr. Colleran will continue as EVP, General Counsel and Corporate Secretary, receive current salary and benefits (but will not accrue vacation), and his equity awards will continue to vest during the transition period per the applicable agreements.
• Payment of separation/retention consideration is conditioned on Mr. Colleran’s compliance with the Transition Agreement, not being terminated for Cause or breach, not resigning, and timely signing the required certificate; the underlying retention terms reference an Executive Retention Agreement dated December 12, 2024.

Why It Matters
The 8-K provides investors with the company’s latest quarterly and annual financial results (earnings/revenue updates are in the attached press release), which can affect near-term stock performance and analyst expectations. The announced transition of the company’s General Counsel is material for corporate governance and continuity of legal and compliance oversight; the agreement preserves operational support through May 1, 2026 and continues equity vesting, which affects timing of share-based compensation. Investors should review the Feb. 26 press release (Exhibit 99.1) and the transition agreement (Exhibit 10.1) for full financial details and the exact terms of the separation arrangements.